文献速递白血病

CD9在中国儿童急性淋巴细胞白血病中的预后意义:来自全国多中心研究的见解

Prognostic implications of CD9 in childhood acute lymphoblastic leukemia: insights from a nationwide multicenter study in China.
PubMed 文献 · Leukemia · 2023-11-25

该研究分析了全国多中心统一治疗的3781例儿童急性淋巴细胞白血病(ALL)病例,通过流式细胞术在诊断样本中定义CD9状态。CD9在88.5%的B-ALL和27.9%的T-ALL病例中表达,在B-ALL中与较低的5年无事件生存率(EFS)和较高的累积复发率(CIR)相关,但在T-ALL中无此关联。CD9的预后影响在中/高危组和微小残留病(尤其诱导缓解第19天)患者中最为显著,且不良影响仅限于特定细胞遗传学亚型,尤其是BCR::ABL1+而非KMT2A重排白血病。多因素分析证实CD9是事件和复发的独立预测因子。

要点

  • CD9在88.5%的B-ALL和27.9%的T-ALL病例中表达。
  • CD9在B-ALL中与较低的5年EFS和较高的CIR相关,但在T-ALL中无此关联。
  • CD9的预后影响在中/高危组和微小残留病患者中最为显著,尤其诱导缓解第19天。

核心结论

  • CD9是儿童ALL事件和复发的独立预测因子,其测量有助于识别需要干预的患者,值得整合到诊断标志物面板中以指导风险分层和及时治疗干预。

研究设计与样本

  • 全国多中心、统一治疗的儿童ALL队列研究,通过流式细胞术在3781例受试者的诊断样本中定义CD9状态。

主要发现

  • CD9在88.5%的B-ALL和27.9%的T-ALL病例中表达。
  • CD9在B-ALL中与较低的5年EFS和较高的CIR相关,但在T-ALL中无此关联。
  • CD9的预后影响在中/高危组和微小残留病患者中最为显著,尤其诱导缓解第19天。
  • CD9的不良影响仅限于特定细胞遗传学亚型,尤其是BCR::ABL1+而非KMT2A重排白血病。
  • 多因素分析证实CD9是事件和复发的独立预测因子。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The outcomes of children with acute lymphoblastic leukemia (ALL) have been incrementally improved with risk-directed chemotherapy but therapy responses remain heterogeneous. Parameters with added prognostic values are warranted to refine the current risk stratification system and inform appropriate therapies. CD9, implicated by our prior single-center study, holds promise as one such parameter. To determine its precise prognostic significance, we analyzed a nationwide, multicenter, uniformly treated cohort of childhood ALL cases, where CD9 status was defined by flow cytometry on diagnostic samples of 3781 subjects. CD9 was expressed in 88.5% of B-ALL and 27.9% of T-ALL cases. It conferred a lower 5-year EFS and a higher CIR in B-ALL but not in T-ALL patients. The prognostic impact of CD9 was most pronounced in the intermediate/high-risk arms and those with minimal residual diseases, particularly at day 19 of remission induction. The adverse impact of CD9 was confined to specific cytogenetics, notably BCR::ABL1+ rather than KMT2A-rearranged leukemia. Multivariate analyses confirmed CD9 as an independent predictor of both events and relapse. The measurement of CD9 offers insights into patients necessitating intervention, warranting its seamless integration into the diagnostic marker panel to inform risk level and timely introduction of therapeutic intervention for childhood ALL.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Leung KT, Cai J, Liu Y, et al. Prognostic implications of CD9 in childhood acute lymphoblastic leukemia: insights from a nationwide multicenter study in China. Leukemia. 2023. PMID: 38001171. doi:10.1038/s41375-023-02089-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。